Drug intelligence / Profile preview

VE-1919

Development stage: Preclinical
Lead developer: Verseon
Modality: Small Molecules
Administration: Oral

Overview

VE-1919 is a preclinical small-molecule drug candidate being developed by Verseon for the treatment of liver disease. The drug was designed using Verseon's proprietary computational platform, which combines molecular physics modeling and artificial intelligence (VersAI) to engineer novel chemical structures atom-by-atom. VE-1919 is currently in the optimization phase of preclinical development, targeting an undisclosed biological pathway involved in liver disease.

Beyond the preview

Go deeper on VE-1919.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VE-1919.

Explore the full profile